Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918857 | 0.85 | CYP19A1 (0.31) | — | |
| SCHEMBL9918876 | 0.85 | CTSL (0.44) | CTSKCYP11B1CYP11B2CTSL | |
| SCHEMBL12251279 | 0.85 | CTSK (0.39) | CTSKCYP11B1CYP11B2CTSL | |
| SCHEMBL9918231 | 0.81 | MKNK1 (0.40) | CYP11B1CYP11B2 | |
| SCHEMBL14790978 | 0.78 | PYCR1 (0.31) | — | |
| SCHEMBL9918873 | 0.78 | CYP2A6 (0.33) | — | |
| SCHEMBL9918848 | 0.76 | RAF1 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL9918855 | 0.76 | CYP3A4 (0.38) | CYP11B1CYP11B2 | |
| SCHEMBL19756421 | 0.73 | PRMT5 (0.40) | CTSKCYP11B1CYP11B2CTSL | |
| SCHEMBL13774836 | 0.72 | CTSK (0.37) | CTSKCYP11B1CYP11B2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | CTSK 2870/4885CYP11B1 708/4885CYP11B2 860/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | CTSK 2774/4885CYP11B1 466/4885CYP11B2 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.